scholarly journals Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients

2003 ◽  
Vol 108 (6) ◽  
pp. 852-856 ◽  
Author(s):  
Vilmos Adleff ◽  
Erika Hitre ◽  
István Köves ◽  
Zsolt Orosz ◽  
Anna Hajnal ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Thymidylate Synthase ◽  
Heterozygote Deficiency ◽  
Genotype Distribution ◽  
Enhancer Region ◽  
Colorectal Cancer Patients

scholarly journals Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients

2015 ◽  
Vol 5 (4) ◽  
pp. e1101205 ◽  
Author(s):  
Pierpaolo Correale ◽  
Cirino Botta ◽  
Elodia Claudio Martino ◽  
Cristina Ulivieri ◽  
Giuseppe Battaglia ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Thymidylate Synthase ◽  
Peptide Vaccination ◽  
Epitope Peptide ◽  
Phase Ib ◽  
Colorectal Cancer Patients

scholarly journals Thymidylate Synthase Gene Polymorphism and Survival of Colorectal Cancer Patients Receiving Adjuvant 5-Fluorouracil

2013 ◽  
Vol 17 (11) ◽  
pp. 799-806 ◽  
Author(s):  
Violetta Sulzyc-Bielicka ◽  
Dariusz Bielicki ◽  
Agnieszka Binczak-Kuleta ◽  
Mariusz Kaczmarczyk ◽  
Wiesława Pioch ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gene Polymorphism ◽  
Cancer Patients ◽  
Thymidylate Synthase ◽  
Colorectal Cancer Patients

scholarly journals Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil

2011 ◽  
Vol 64 (3) ◽  
pp. 242-248 ◽  
Author(s):  
Marina Vignoli ◽  
Stefania Nobili ◽  
Cristina Napoli ◽  
Anna Laura Putignano ◽  
Maria Morganti ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Thymidylate Synthase ◽  
Colorectal Cancer Patients

Prognostic value of thymidylate synthase and cox-2 expression in colorectal cancer patients' tumors

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3731-3731
Author(s):  
M. Aliustaoglu ◽  
M. Gumus ◽  
A. Midi ◽  
C. A. Celikel ◽  
M. Ekenel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Thymidylate Synthase ◽  
Prognostic Value ◽  
Cox 2 ◽  
Colorectal Cancer Patients

Evaluation of thymidylate synthase and ERCC1 mRNA levels as predictive markers in colorectal cancer patients treated with S-1 and oxaliplatin

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15071-e15071
Author(s):  
H. Kuramochi ◽  
K. Hayashi ◽  
G. Nakajima ◽  
H. Kamikozuru ◽  
M. Yamamoto
Keyword(s):  
Colorectal Cancer ◽  
Mrna Expression ◽  
Real Time ◽  
Cancer Patients ◽  
Thymidylate Synthase ◽  
Excision Repair ◽  
Mrna Levels ◽  
Expression Levels ◽  
Colorectal Cancer Patients ◽  
Mrna Expression Levels

e15071 Background: Oxaliplatin has been widely used for the treatment of colorectal cancer. The mechanism of action of platinum compounds such as oxaliplatin is to bind to a DNA molecule in the form of a platinum-DNA-adduct. Excision repair cross complementation group 1 (ERCC1), which plays a major role in the nucleotide excision pathway, has a polymorphism in codon 118, and is reported to be associated with a resistance to platinum-based therapy. Thymidylate synthase (TS) and dehydropyrimidine dehydrogenase (DPD) are key enzymes of 5-FU metabolism and are well known to be associated with a response to 5-FU-based therapy. Methods: Twenty-one colorectal cancer patients (male:female = 7:14; median age, 65) treated with a combination of oxaliplatin and S-1 as a first-line therapy were analyzed for ERCC1 codon 118 polymorphism and the mRNA expression levels of TS, ERCC1, and DPD. Formalin-fixed paraffin- embedded surgical specimens were used and t-RNA and DNA were extracted. The mRNA expression levels were measured using real-time RT-PCR, and the polymorphism was analyzed using the allelic discrimination method together with real-time PCR. Results: No correlation was observed between ERCC1 codon118 polymorphism and any response to the chemotherapy. ERCC1 mRNA levels tended to be higher in the patients with wild-type homozygous alleles in codon 118 than in those with at least one mutant allele(1.19 vs.0.68: p= 0.15). Patients with both high TS and ERCC1 mRNA levels showed a significantly lower response rate than the others (25% vs. 67%, p=0.02). No relationship was seen between DPD mRNA expression levels and the response. Conclusions: The mRNA expression levels of TS and ERCC1 appear to be useful markers for the treatment of S-1 and oxaliplatin. No particular usefulness of ERCC1 codon 118 polymorphism was verified. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document